HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mary Ann Peberdy Selected Research

Carbon Dioxide

10/2013Effects of respiratory exchange ratio on the prognostic value of peak oxygen consumption and ventilatory efficiency in patients with systolic heart failure.
5/2012Patients with heart failure in the "intermediate range" of peak oxygen uptake: additive value of heart rate recovery and the minute ventilation/carbon dioxide output slope in predicting mortality.
10/2010Development of a cardiopulmonary exercise prognostic score for optimizing risk stratification in heart failure: the (P)e(R)i(O)dic (B)reathing during (E)xercise (PROBE) study.
11/2009The lowest VE/VCO2 ratio during exercise as a predictor of outcomes in patients with heart failure.
11/2008The partial pressure of resting end-tidal carbon dioxide predicts major cardiac events in patients with systolic heart failure.
11/2008Prognostic characteristics of cardiopulmonary exercise testing in caucasian and African American patients with heart failure.
10/2008Prognostic usefulness of dyspnea versus fatigue as reason for exercise test termination in patients with heart failure.
9/2008The added prognostic value of ventilatory efficiency to the Weber classification system in patients with heart failure.
5/2008The ventilatory classification system effectively predicts hospitalization in patients with heart failure.
2/2008Relation of the prognostic value of ventilatory efficiency to body mass index in patients with heart failure.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Mary Ann Peberdy Research Topics

Disease

37Heart Arrest (Cardiac Arrest)
07/2022 - 09/2003
28Heart Failure
06/2017 - 10/2002
10Cardiovascular Diseases (Cardiovascular Disease)
09/2013 - 05/2007
7Ventricular Fibrillation
07/2022 - 01/2012
7Out-of-Hospital Cardiac Arrest
10/2020 - 08/2005
6Stroke (Strokes)
05/2010 - 11/2007
5Hypothermia
12/2020 - 01/2010
4Reperfusion Injury
11/2021 - 01/2009
3Brain Injuries (Brain Injury)
11/2010 - 10/2006
2Brain Edema (Cerebral Edema)
11/2021 - 07/2021
2ST Elevation Myocardial Infarction
01/2015 - 09/2009
2Dyspnea (Shortness of Breath)
10/2010 - 10/2008
2Post-Cardiac Arrest Syndrome
01/2010 - 10/2009
2Coma (Comas)
05/2008 - 10/2006
1Neurologic Manifestations (Neurological Manifestations)
01/2022
1Brain Ischemia (Cerebral Ischemia)
11/2021
1COVID-19
10/2021
1Inflammation (Inflammations)
01/2021
1Opiate Overdose
01/2020
1Myocardial Infarction
01/2015
1Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder)
07/2013
1Ventricular Tachycardia
01/2012
1Hypertension (High Blood Pressure)
03/2011
1Dyslipidemias (Dyslipidemia)
03/2011
1Cardiac Arrhythmias (Arrythmia)
11/2010
1Bradycardia
11/2010
1Tachycardia (Tachyarrhythmias)
11/2010
1Death (Near-Death Experience)
10/2010
1Hyperglycemia
06/2009
1Hypoglycemia (Reactive Hypoglycemia)
06/2009
1Systolic Heart Failure
11/2008
1Atrial Fibrillation
12/2003
1Bundle-Branch Block (Fascicular Block)
12/2003

Drug/Important Bio-Agent (IBA)

17Carbon DioxideIBA
10/2013 - 08/2003
7Oxygen (Dioxygen)IBA
05/2012 - 10/2002
3Clostridium perfringens epsilon-toxinIBA
10/2010 - 01/2006
2N- (1,2,3,5,6,7- hexahydro- S- indacen- 4- ylcarbamoyl)- 4- (2- hydroxy- 2- propanyl)- 2- furansulfonamideIBA
01/2022 - 11/2021
2IceIBA
01/2010 - 12/2006
1N- (4- (N- (3- methoxypyrazin- 2- yl)sulfamoyl)phenyl)- 3- (5- nitrothiophene- 2- yl)acrylamideIBA
07/2022
1Deferoxamine (Desferal)FDA LinkGeneric
01/2022
1diazonaphthalenedisulfonic acid (NDS)IBA
01/2022
1InterleukinsIBA
11/2021
1Phosphopyruvate Hydratase (Enolase)IBA
11/2021
1InflammasomesIBA
11/2021
1CalciumIBA
08/2021
1Polyethylene (Polythene)IBA
07/2021
1Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA
01/2021
1Ascorbic Acid (Vitamin C)FDA LinkGeneric
01/2021
1Cannabinoid Receptor AgonistsIBA
12/2020
1LipidsIBA
12/2020
1PH.3IBA
12/2020
1AntidotesIBA
01/2020
1Naloxone (Narcan)FDA LinkGeneric
01/2020
1Neurotensin Receptors (Neurotensin Receptor)IBA
01/2019
1NeurotensinIBA
01/2019
1Epinephrine (Adrenaline)FDA LinkGeneric
01/2018
1salicylhydroxamic acid (SHAM)IBA
01/2018
1Adrenergic Receptors (Adrenergic Receptor)IBA
01/2018
1alpha 1-Antitrypsin (alpha 1 Antitrypsin)IBA
01/2015
1C-Reactive ProteinIBA
01/2015
14-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA
07/2013
1Biological ProductsIBA
03/2012
1SmokeIBA
03/2011
1Type 5 Cyclic Nucleotide PhosphodiesterasesIBA
10/2010
1Sildenafil Citrate (Viagra)FDA Link
10/2010
1Dacarbazine (DIC)FDA LinkGeneric
10/2010
1Estrogens (Estrogen)FDA Link
05/2010
1ProgesteroneFDA LinkGeneric
05/2010
1N 30IBA
01/2010
1Biomarkers (Surrogate Marker)IBA
09/2009
1TroponinIBA
09/2009
1Complement System Proteins (Complement)IBA
08/2009
1Glucose (Dextrose)FDA LinkGeneric
06/2009
1Blood Glucose (Blood Sugar)IBA
06/2009
1Norepinephrine (Noradrenaline)FDA LinkGeneric
12/2003

Therapy/Procedure

27Resuscitation
07/2022 - 06/2006
17Cardiopulmonary Resuscitation (CPR)
07/2022 - 08/2005
12Heart-Assist Devices
06/2017 - 05/2007
10Induced Hypothermia
12/2020 - 10/2006
7Transplantation
09/2013 - 05/2007
7Critical Care (Surgical Intensive Care)
11/2010 - 10/2006
4Anesthesia
01/2010 - 12/2008
3Heart Transplantation (Grafting, Heart)
09/2012 - 11/2008
2Therapeutics
06/2017 - 11/2010
2Defibrillators (Defibrillator)
11/2010 - 09/2003
1Artificial Respiration (Mechanical Ventilation)
11/2021
1Advanced Cardiac Life Support (Life Support, Advanced Cardiac)
10/2021
1Vagus Nerve Stimulation
01/2018
1Artificial Heart (Artificial Hearts)
06/2017
1Organ Transplantation
03/2013
1Electric Countershock (Cardioversion)
11/2010
1Hormone Replacement Therapy (Therapy, Hormone Replacement)
10/2003